ARCHIVES

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Abbott’s HER-2 DNA Probe Kit.

January 25, 2002

Guest Editorial: Chernobyl Doctor’s Notes From Fukushima

April 1, 2011

NCI Makes First NRS Award – 13 Institution Grants; 150 Individuals Pending: Lepovetsky Training Chief

April 4, 1975

ACS Cancer Control Research Grant Programs Available

May 5, 2000

HHS Forms Patient Safety Task Force; Henry Ford Health System Receives $40M.

April 27, 2001

Kulig Will Oversee Outcomes Research at NCCN

September 30, 2011